Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

被引：3

作者：

Hajek, Roman ^{[1
,2
]}

Minarik, Jiri ^{[3
]}

Straub, Jan ^{[4
]}

Pour, Ludek ^{[5
]}

Jungova, Alexandra ^{[6
]}

Berdeja, Jesus G. ^{[7
]}

Boccadoro, Mario ^{[8
]}

Brozova, Lucie ^{[9
]}

Spencer, Andrew ^{[10
]}

van Rhee, Frits ^{[11
]}

Vela-Ojeda, Jorge ^{[12
]}

Thompson, Michael A. ^{[13
]}

Abonour, Rafat ^{[14
,15
]}

Chari, Ajai ^{[16
]}

Cook, Gordon ^{[17
]}

Costello, Caitlin L. ^{[18
]}

Davies, Faith E. ^{[19
]}

Hungria, Vania T. M. ^{[20
]}

Lee, Hans C. ^{[21
]}

Leleu, Xavier ^{[22
]}

Puig, Noemi ^{[23
]}

Rifkin, Robert M. ^{[24
]}

Terpos, Evangelos ^{[25
]}

Usmani, Saad Z. ^{[26
]}

Weisel, Katja C. ^{[27
]}

Zonder, Jeffrey A. ^{[28
]}

Barinova, Magda ^{[29
]}

Kuhn, Matyas ^{[29
]}

Silar, Jiri ^{[29
]}

Capkova, Lenka ^{[29
]}

Galvez, Kenny ^{[30
]}

Lu, Jin ^{[31
]}

Skacel, Tomas ^{[32
,33
,34
]}

Elliott, Jennifer ^{[32
]}

Demers, Brittany ^{[35
]}

Marie, Dawn ^{[32
]}

Ren, Kaili ^{[32
]}

Maisnar, Vladimir ^{[36
]}

机构：

[1] Univ Hosp Ostrava, Dept Hematooncol, Ostrava, Czech Republic

[2] Univ Ostrava, Fac Med, Ostrava, Czech Republic

[3] Univ Hosp Olomouc, Olomouc, Czech Republic

[4] Gen Teaching Hosp, Fac Med 1, Dept Med 1, Clin Dept Hematol, Prague, Czech Republic

[5] Univ Hosp, Hematol, Brno, Czech Republic

[6] Fac Hosp Pilsen, Plzen, Czech Republic

[7] Sarah Cannon Ctr Blood Canc, Nashville, TN USA

[8] Univ Torino, Div Hematol, Turin, Italy

[9] Masaryk Univ, Inst Biostat & Anal, Fac Med, Brno, Czech Republic

[10] Monash Univ, Alfred Hlth, Dept Clin Haematol, Melbourne, Vic, Australia

[11] Univ Arkansas Med Sci, Myeloma Ctr, Little Rock, AR 72205 USA

[12] UMAE Especialidades Ctr Med La Raza IMSS, Mexico City, Mexico

[13] Advocate Aurora Hlth, Aurora Res Inst, Aurora Canc Care, Aurora, CO USA

[14] IU Sch Med, Indianapolis, IN USA

[15] Indiana Univ Sch Med, Hematol Oncol, Indianapolis, IN 46202 USA

[16] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[17] Leeds Teaching Hosp, Dept Haematol, Clin Trials Res Unit, NIHR Leeds IVD Cooperat, Leeds, W Yorkshire, England

[18] Univ Calif San Diego, Dept Med, Div Blood & Marrow Transplantat, Moores Canc Ctr, La Jolla, CA 92093 USA

[19] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

[20] Clin Sao Germano & Santa Casa Med Sch, Dept Hematol, Sao Paulo, Brazil

[21] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[22] CHU Poitiers, Pole Reg Cancerol, Poitiers, France

[23] Hosp Univ Salamanca Hematol, Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain

[24] US Oncol Res, Rocky Mt Canc Ctr, Hematol Res, Yampa Valley Med Ctr, Frisco, TX USA

[25] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

[26] Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA

[27] Univ Med Ctr Hamburg Eppendorf, Hematol Stem Cell Transplantat, Dept Oncol, Sect Pneumol, Hamburg, Germany

[28] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dept Malignant Hematol, Detroit, MI USA

[29] Inst Biostat & Anal Ltd, Brno, Czech Republic

[30] Hosp Pablo Tobon Uribe, Medellin, Colombia

[31] Peking Univ Peoples Hosp, Natl Clin Res Ctr Hematol Dis, Beijing, Peoples R China

[32] Millennium Pharmaceut Inc, Cambridge, MA USA

[33] Charles Univ Prague, Fac Med 1, Dept Med 1, Prague, Czech Republic

[34] Gen Hosp Prague, Prague, Czech Republic

[35] Millennium Pharmaceut Inc, Oncol, Cambridge, MA USA

[36] Charles Univ Prague, Fac Hosp, Dept Med Haematol 4, Hradec Kralove, Czech Republic

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-126606

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1845

引用

页数：7

共 50 条

[1] Closing the efficacy and effectiveness gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) patients (Pts) treated with Ixazomib-lenalidomide-Dexamethasone (IRd) in routine clinical practice remain comparable to the outcomes reported in the phase 3 TOURMALINE-MM1 study
Weisel, K.
Hajek, R.
Minarik, J.
Straub, J.
Pour, L.
Jungova, A.
Berdeja, J.
Boccadoro, M.
Brozova, L.
Spencer, A.
Van Rhee, F.
Vela-Ojeda, J.
Thompson, M.
Abonour, R.
Chari, A.
Cook, G.
Costello, C.
Davies, F.
Hungria, V
Lee, H. C.
Leleu, X.
Puig, N.
Rifkin, R.
Terpos, E.
Usmani, S.
Zonder, J.
Barinova, M.
Kuhn, M.
Silar, J.
Capkova, L.
Galvez, K.
Lu, J.
Skacel, T.
Elliott, J.
Demers, B.
Stull, D. M.
Ren, K.
Maisnar, V
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 96 - 97
[2] Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma
Hajek, Roman
Minarik, Jiri
Straub, Jan
Pour, Ludek
Jungova, Alexandra
Berdeja, Jesus G.
Boccadoro, Mario
Brozova, Lucie
Spencer, Andrew
Rhee, Frits van
Vela-Ojeda, Jorge
Thompson, Michael A.
Abonour, Rafat
Chari, Ajai
Cook, Gordon
Costello, Caitlin L.
Davies, Faith E.
Hungria, Vania T. M.
Lee, Hans C.
Leleu, Xavier
Puig, Noemi
Rifkin, Robert M.
Terpos, Evangelos
Usmani, Saad Z.
Weisel, Katja C.
Zonder, Jeffrey A.
Barinova, Magda
Kuhn, Matyas
Silar, Jiri
Capkova, Lenka
Galvez, Kenny
Lu, Jin
Elliott, Jennifer
Stull, Dawn Marie
Ren, Kaili
Maisnar, Vladimir
[J]. FUTURE ONCOLOGY, 2021, 17 (19) : 2499 - 2512
[3] The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice
Leleu, Xavier
Boccadoro, Mario
Lee, Hans C.
Zonder, Jeffrey A.
Macro, Magaret
Ramasamy, Karthik
Hulin, Cyrille
Silar, Jiri
Kuhn, Matyas
Ren, Kaili
Bent-Ennakhil, Nawal
Bouillie, Sylvie
Cherepanov, Dasha
Stull, Dawn Marie
Terpos, Evangelos
[J]. BLOOD, 2021, 138
[4] EFFICACY AND SAFETY OF ORAL IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) VS PLACEBO-RD IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: IMPACT OF PRIOR THERAPY IN THE PHASE 3 TOURMALINE-MM1 STUDY
Mateos, M. V.
Masszi, T.
Grzasko, N.
Hansson, M.
Sandhu, I.
Pour, L.
Viterbo, L.
Jackson, S.
Stoppa, A. M.
Gimsing, P.
Hamadani, M.
Borsaru, G.
Berg, D.
Lin, J.
van de Velde, H.
Richardson, P.
Moreau, P.
[J]. HAEMATOLOGICA, 2016, 101 : 527 - 527
[5] IXAZOMIB PLUS LENALIDOMIDE-DEXAMETHASONE (IRD) VS PLACEBO-RD IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): CHINA CONTINUATION OF TOURMALINE-MM1
Hou, J.
Jin, J.
Xu, Y.
Wu, D.
Ke, X.
Daobin, Z.
Lu, J.
Du, X.
Chen, X.
Li, J.
Liu, J.
Wang, B.
Zhang, X.
Wang, H.
van de Velde, H.
Richardson, P.
Moreau, P.
[J]. HAEMATOLOGICA, 2016, 101 : 540 - 540
[6] Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1.
Mateos, Maria-Victoria
Masszi, Tamas
Grzasko, Norbert
Hansson, Markus
Sandhu, Irwindeep
Pour, Ludek
Viterbo, Luisa
Jackson, Sharon R.
Stoppa, Anne-Marie
Gimsing, Peter
Hamadani, Mehdi
Borsaru, Gabriela
Berg, Deborah
Lin, Jianchang
Van De Velde, Helgi
Richardson, Paul G.
Moreau, Philippe
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[7] IMPACT OF CYTOGENETIC RISK STATUS ON EFFICACY AND SAFETY OF IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) VS PLACEBO-RD IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IN THE GLOBAL TOURMALINE-MM1 STUDY
Avet-Loiseau, H.
Bahlis, N.
Chng, W. J.
Masszi, T.
Viterbo, L.
Pour, L.
Ganly, P.
Palumbo, A.
Cavo, M.
Langer, C.
Pluta, A.
Nagler, A.
Kumar, S.
Ben-Yehuda, D.
Rajkumar, S. V.
Miguel, J. San
Berg, D.
Lin, J.
van de Velde, H.
Badola, S.
Gao, F.
Zhange, J.
Shen, L.
Li, B.
Esseltine, D. L.
di Bacco, A.
Moreau, P.
Richardson, P.
[J]. HAEMATOLOGICA, 2016, 101 : 80 - 80
[8] Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) - Effectiveness in Routine Clinical Practice Is Similar to the Efficacy in the Phase 3 Tourmaline-MM1 Trial: A Pooled Analysis from the Insight MM Observational Study and the Czech Registry of Monoclonal Gammopathies (RMG)
Hajek, Roman
Terpos, Evangelos
Lee, Hans C.
Chari, Ajai
Costello, Caitlin L.
Puig, Noemi
Leleu, Xavier
Berdeja, Jesus G.
Davies, Faith E.
Weisel, Katja
Usmani, Saad Z.
Hungria, Vania T. M.
Boccadoro, Mario
Rifkin, Robert M.
Zonder, Jeffrey A.
Cook, Gordon
Brozova, Lucie
Barinova, Magda
Ren, Kaili
Cacioppo, Roxanne
Skacel, Tomas
Stull, Dawn Marie
Maisnar, Vladimir
[J]. BLOOD, 2018, 132
[9] Quality of Life (QoL) and Clinical Outcomes in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Ixazomib-Lenalidomide-Dexamethasone (IRd) in a Real-World Setting
Ionova, Tatyana
Ado, Elena
Anchukova, Lyudmila
Babich, Elena
Dasheeva, Dolgorzhap
Demchenkova, Marina
Dubov, Sergei
Esenina, Tatiana
Ivanova, Lyudmila
Kaplanov, Kamil
Kopylova, Anna
Kochkareva, Yulia
Kravchuk, Tatiana
Levanov, Alexander
Li, Olga
Mitina, Tatiana
Nikitina, Tatiana
Porfirieva, Natalia
Rimashevskaya, Elena
Rukavitsyn, Oleg
Saraeva, Natalia
Savinova, Marina
Shelekhova, Tatiana
Simashova, Polina
Shirokova, Mariya
Vinogradova, Olga
Volkova, Svetlana
Zinkovskaya, Anna
[J]. BLOOD, 2020, 136
[10] Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
Mateos, Maria-Victoria
Masszi, Tamas
Grzasko, Norbert
Hansson, Markus
Sandhu, Irwindeep
Pour, Ludek
Viterbo, Luisa
Jackson, Sharon R.
Stoppa, Anne-Marie
Gimsing, Peter
Hamadani, Mehdi
Borsaru, Gabriela
Berg, Deborah
Lin, Jianchang
Di Bacco, Alessandra
van de Velde, Helgi
Richardson, Paul G.
Moreau, Philippe
[J]. HAEMATOLOGICA, 2017, 102 (10) : 1767 - 1775

← 1 2 3 4 5 →